Trevi Therapeutics, Inc. (TRVI) News

Trevi Therapeutics, Inc. (TRVI): $4.11

-0.16 (-3.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter TRVI News Items

TRVI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TRVI News Highlights

  • For TRVI, its 30 day story count is now at 3.
  • Over the past 23 days, the trend for TRVI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest TRVI News From Around the Web

Below are the latest news stories about Trevi Therapeutics Inc that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Why Are Trevi Therapeutics Shares Surging During Premarket Thursday?

Trevi Therapeutics Inc (NASDAQ: TRVI) has announced positive interim analysis results from Phase 2 CANAL trial of Haduvio (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough. The company conducted a statistical analysis to assess the probability of success of CANAL based on the interim data. The interim analysis (N=26) was statistically significant on the primary efficacy endpoint, demonstrating a 52% placebo-adjusted reduction in the geometric mean perce

Yahoo | February 24, 2022

Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept. Further patient recruitment in the trial will stop based on the strength and consistency of the data.

Yahoo | February 24, 2022

Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN

Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that it has completed enrollment in its Phase 2b/3 PRISM trial for pruritus associated with prurigo nodularis (PN) and expects to report top-line data in the second quarter of 2022.

Yahoo | February 1, 2022

Here's Why Trevi Therapeutics, Inc. (TRVI) Could be Great Choice for a Bottom Fisher

Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo | January 25, 2022

Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Trevi Therapeutics (TRVI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Stryker (SYK – Research Report) and Trevi Therapeutics (TRVI – Research Report). Stryker (SYK) In a report released today, Michael Matson from Needham maintained a Hold rating on Stryker. The company's shares closed last Thursday at $273.16, close to its 52-week high of $281.16. According to TipRanks.

Christine Brown on TipRanks | January 6, 2022

Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications

Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that it expects to perform an interim statistical update in the first quarter of 2022 for its ongoing Phase 2 CANAL trial of Haduvio in patients suffering from chronic cough due to idiopathic pulmonary fibrosis (IPF). Trevi also announced that it expects to end enrollment in

Yahoo | January 5, 2022

Trevi Therapeutics (NASDAQ:TRVI) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Trevi Therapeutics (NASDAQ:TRVI) from a hold rating to a buy rating in a report released on Tuesday, Zacks.com reports. Zacks Investment Research currently has $0.75 price objective on the stock. According to Zacks, Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization []

Dakota Financial News | December 24, 2021

Trevi Therapeutics to Attend Multiple Conferences in January 2022

Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that senior management will be participating in the 11th Annual LifeSci Partners Corporate Access Event taking place virtually from January 5-7, the Dermatology Summit taking place virtually on January 7, the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13 a

Yahoo | December 16, 2021

Trevi Therapeutics (NASDAQ:TRVI) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Trevi Therapeutics (NASDAQ:TRVI) from a hold rating to a buy rating in a research report sent to investors on Friday, Zacks.com reports. They currently have $1.00 price objective on the stock. According to Zacks, Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and []

Transcript Daily | December 13, 2021

Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Zacks Investment Research to Hold

Trevi Therapeutics (NASDAQ:TRVI) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Saturday, Zacks.com reports. According to Zacks, Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company []

Transcript Daily | December 4, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4446 seconds.